热门资讯> 正文
Citius Pharmaceuticals GAAP每股收益为-3.38美元
2025-12-24 05:35
- Citius Pharmaceuticals press release (CTXR): FY GAAP EPS of -$3.38.
- Cash and cash equivalents of $4.3 million as of September 30, 2025;
- Citius Pharma did not report revenues for the year;
- R&D expenses were $9.2 million for the full year ended September 30, 2025, compared to $11.9 million for the full year ended September 30, 2024;
- G&A expenses were $18.5 million for the full year ended September 30, 2025, compared to $18.2 million for the full year ended September 30, 2024;
- Stock-based compensation expense was $10.8 million for the full year ended September 30, 2025, compared to $11.8 million for the full year ended September 30, 2024; and,
More on Citius Pharmaceuticals
- Citius Pharmaceuticals GAAP EPS of -$3.38 misses by $0.25
- Citius Oncology announces $18 million registered direct offering
- Seeking Alpha’s Quant Rating on Citius Pharmaceuticals
- Historical earnings data for Citius Pharmaceuticals
- Financial information for Citius Pharmaceuticals
推荐文章
美股机会日报 | 阿里发布千问3.5！性能媲美Gemini 3；马斯克称Cybercab将于4月开始生产
港股周报 | 中国大模型“春节档”打响！智谱周涨超138%；巨亏超230亿！美团周内重挫超10%
一周财经日历 | 港美股迎“春节+总统日”双假期！万亿零售巨头沃尔玛将发财报
一周IPO | 赚钱效应持续火热！年内24只上市新股“0”破发；“图模融合第一股”海致科技首日飙涨逾242%
从软件到房地产，美国多板块陷入AI恐慌抛售潮
Meta计划为智能眼镜添加人脸识别技术
危机四伏，市场却似乎毫不在意
财报前瞻 | 英伟达Q4财报放榜在即！高盛、瑞银预计将大超预期，两大关键催化将带来意外惊喜？
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
